Lifecore Biomedical (LFCR) Projected to Post Earnings on Friday

Lifecore Biomedical (NASDAQ:LFCR) is expected to be announcing its Q1 2026 results before the market opens on Friday, October 3rd. Analysts expect Lifecore Biomedical to post earnings of ($0.29) per share and revenue of $26.68 million for the quarter. Lifecore Biomedical has set its FY 2026 guidance at EPS.Investors can check the company’s upcoming Q1 2026 earningsummary page for the latest details on the call scheduled for Friday, October 3, 2025 at 8:30 AM ET.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The business had revenue of $36.44 million for the quarter, compared to the consensus estimate of $35.36 million. Lifecore Biomedical had a negative return on equity of 846.51% and a negative net margin of 31.70%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Stock Performance

NASDAQ LFCR opened at $6.81 on Friday. The firm has a 50-day moving average price of $7.47 and a two-hundred day moving average price of $7.08. Lifecore Biomedical has a 12-month low of $4.33 and a 12-month high of $8.85. The company has a market capitalization of $255.17 million, a P/E ratio of -5.20 and a beta of 0.64. The company has a quick ratio of 1.77, a current ratio of 2.84 and a debt-to-equity ratio of 113.76.

Analysts Set New Price Targets

Several brokerages recently issued reports on LFCR. Wall Street Zen upgraded Lifecore Biomedical from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. KeyCorp initiated coverage on Lifecore Biomedical in a research report on Wednesday, September 3rd. They set a “sector weight” rating for the company. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Lifecore Biomedical presently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Hedge Funds Weigh In On Lifecore Biomedical

Hedge funds and other institutional investors have recently modified their holdings of the business. State of Wyoming acquired a new position in shares of Lifecore Biomedical during the 2nd quarter worth $69,000. The Manufacturers Life Insurance Company acquired a new position in Lifecore Biomedical during the second quarter worth about $88,000. Invesco Ltd. acquired a new position in Lifecore Biomedical during the second quarter worth about $3,081,000. Rhumbline Advisers boosted its stake in shares of Lifecore Biomedical by 54.0% in the 2nd quarter. Rhumbline Advisers now owns 38,091 shares of the company’s stock valued at $309,000 after purchasing an additional 13,361 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Lifecore Biomedical by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 775,493 shares of the company’s stock valued at $6,299,000 after purchasing an additional 24,995 shares during the last quarter. Institutional investors own 83.36% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.